InspireMD Announces PIs for C-GUARDIANS II Trial Evaluating the SwitchGuard Neuroprotection System

February 12, 2024—InspireMD, Inc. named Patrick Geraghty, MD, and Patrick Muck, MD, as the lead Principal Investigators (PIs) for the company’s upcoming C-GUARDIANS II clinical trial for the SwitchGuard neuroprotection system (NPS). 

According to the company, the C-GUARDIANS II study will aim to advance clearance of SwitchGuard NPS and associated tools, which are designed to allow the treating physician to reverse cerebral blood flow during a transcarotid artery revascularization procedure, preventing embolic debris generated during the procedure from traveling to the brain by passing the blood through the filter enclosed within the SwitchGuard before returning it to the patient to minimize blood loss.

Dr. Geraghty is Professor of Surgery and Radiology, Section of Vascular Surgery at Washington University School of Medicine in St. Louis, Missouri. Dr. Muck is Program Director and Chief of Vascular Surgery at Good Samaritan Hospital in Cincinnati, Ohio.

Marvin Slosman, CEO of InspiredMD, commented in the company’s announcement, “We are very pleased that Drs. Geraghty and Muck, both recognized leaders in the field of vascular surgery, have agreed to lead the execution of this important trial, planned to start later this year.”

In addition to appointing the C-GUARDIANS II PIs, InspireMD also announced that Dr. William Gray will act as an advisor to the company. Dr. Gray is the System Chief of the Cardiovascular Division at Main Line Health in Wynnewood, Pennsylvania, and a Professor of Medicine at Thomas Jefferson University in Philadelphia, Pennsylvania. 

“We look forward to [Dr. Gray’s] contributions given his vast experience and knowledge in the field of carotid intervention,” added Mr. Slosman.

The company also developed the CGuard embolic prevention carotid stent system to prevent stroke as a part of its portfolio of devices, which reported 30-day results from the C-GUARDIANS pivotal trial in November 2023.